IL7 (interleukin 7) was first identified in 1988 in a bone marrow culture as a factor that facilitated murine B cell precursors growth. It is a cytokine produced by non-lymphoid cells in lymphoid organs. In humans, it is also produced by keratinocytes, peripheral blood dendritic cells,follicular dendritic cells, intestinal epithelial cells, hepatic tissue, endothelial cells, smooth muscle cells and fibroblasts. IL7 gene is localized to human chromosome 8q12-q13. It is a glycoprotein with a four a-helix structure with a hydrophobic core. Recombinant human IL-7 is a 17.4 kDa protein containing 153 amino acid residues.
IL7 (interleukin 7) is crucial for lymphocyte survival and development. It is required for the survival, proliferation and the rearrangement of certain TCR (T cell receptor) genes in earliest thymus stem cells. During later stages, in thymus, it is essential for the positive selection of CD8 cells. IL7 is also essential for the survival and homeostatic proliferation of mature T cells which have left the thymus. In patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT), increased IL-7 plasma levels in the early post-transplant period is linked with suppressed T cell counts and elevated risks of acute graft-versus-host disease (aGVHD) and mortality. IL7 shows varied tear expression levels during different stages of Graves′ ophthalmopathy (GO), and thus, might be implicated in the pathogenesis of GO.
Lyophilized from 10 mM Acetic Acid.
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.